
    
      Study subjects receive either Rebif or Avonex. Rebif is applied s.c. at a dose of 44 µg on
      day 1, day 3, day 5 and day 8, Avonex i.m. at a dose of 30µg on day 1 and 8. Blood samples
      are taken before application and on day 1 and 8 at 1 / 6 / 12 /24 hrs after Rebif/Avonex
      application to analyse the occuring immune response. The total duration of the trial for the
      individual subject are 9 days. An MRI ist performed before the first application of IMP and
      at the end of the study to investigate the correlation of Rebif/Avonex application and
      depression.
    
  